Published in

Wiley, Diabetes, Obesity and Metabolism, 3(14), p. 204-213, 2011

DOI: 10.1111/j.1463-1326.2011.01491.x

Links

Tools

Export citation

Search in Google Scholar

Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types?

Journal article published in 2011 by Eleonore Fröhlich ORCID, Richard Wahl
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

The risk for differentiated thyroid cancer, like for many other types of cancer, is increased in obese individuals and people with intermediate hyperglycaemia. The incidence of all cancers, with the exception of thyroid cancer, is also increased in type 2 diabetes mellitus patients. The review compares the prevalence of thyroid carcinoma and other cancers in obese, people with intermediate hyperglycaemia and patients with diabetes and summarizes mode of action and anti-tumourigenic effect of common antidiabetic medications. The over-expression of dipeptidyl peptidase IV in the tumours, not seen in the other cancer types, is suggested as a potential reason for the unique situation in thyroid cancer.